PDS Biotechnology (PDSB) has shared an announcement.
PDS Biotechnology Corporation has updated its sales agreement with B. Riley Securities, Inc. and H.C. Wainwright & Co., allowing the company to sell up to $50 million worth of common stock at its discretion. The sales, to be conducted as needed through “at-the-market” offerings, will be executed under a previously filed registration statement. The agents will receive a 3% commission on sales and have been granted customary indemnification rights. The sales program is flexible, with no obligation for PDS Biotechnology to sell the stock, and can be terminated at any time upon certain conditions being met.
Learn more about PDSB stock on TipRanks’ Stock Analysis page.
